These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Failure to attain stretched penile length after intracavernosal injection of a vasodilator agent is predictive of veno-occlusive dysfunction on penile duplex Doppler ultrasonography. Yafi FA; Libby RP; McCaslin IR; Sangkum P; Sikka SC; Hellstrom WJ Andrology; 2015 Sep; 3(5):919-23. PubMed ID: 26235901 [TBL] [Abstract][Full Text] [Related]
6. [Some aspects of the use of prostaglandin E1 in cases of erectile dysfunction]. Fekete F Orv Hetil; 1997 Jun; 138(25):1631-4. PubMed ID: 9265144 [TBL] [Abstract][Full Text] [Related]
7. [Epidemiology and treatment of long-term male impotence]. Andriani E; Cosentina R Minerva Cardioangiol; 1996 May; 44(5):237-42. PubMed ID: 8927252 [TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E1 in the medical management of erectile dysfunction in a genito-urinary medicine clinic. Armstrong DK; Convery A; Dinsmore WW Ulster Med J; 1994 Apr; 63(1):18-22. PubMed ID: 8658990 [TBL] [Abstract][Full Text] [Related]
9. Ketanserin plus prostaglandin E1 (PGE-1) as intracavernosal therapy for patients with erectile dysfunction unresponsive to PGE-1 alone. Mirone V; Imbimbo C; Fabrizio F; Longo N; Palmieri A Br J Urol; 1996 May; 77(5):736-9. PubMed ID: 8689122 [TBL] [Abstract][Full Text] [Related]
10. The rationale for prostaglandin E1 (alpha-alprostadil) in the management of male impotence. Porst H Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():539-44. PubMed ID: 7732903 [No Abstract] [Full Text] [Related]
11. [Erectile dysfunction in men under 39]. Sasaki H; Goto R; Sato M; Ota M; Ikeuchi T Nihon Rinsho; 2002 Jun; 60 Suppl 6():469-72. PubMed ID: 12166203 [No Abstract] [Full Text] [Related]
12. [Prostaglandin E1 (PGE1) in diagnosis and long-term therapy of erectile dysfunction]. Derouet H; Weirauch A; Bewermeier H Urologe A; 1996 Jan; 35(1):62-7. PubMed ID: 8851852 [TBL] [Abstract][Full Text] [Related]
13. Intracavernous injection of alprostadil for erectile dysfunction. Med Lett Drugs Ther; 1995 Sep; 37(958):83-4. PubMed ID: 7674992 [No Abstract] [Full Text] [Related]
14. Is diabetic neuropathy responsible for diabetic impotence? Takanami M; Nagao K; Ishii N; Miura K; Shirai M Urol Int; 1997; 58(3):181-5. PubMed ID: 9188140 [TBL] [Abstract][Full Text] [Related]
15. Poor response to alprostadil ICI test is associated with arteriogenic erectile dysfunction and higher risk of major adverse cardiovascular events. Rastrelli G; Corona G; Monami M; Melani C; Balzi D; Sforza A; Forti G; Mannucci E; Maggi M J Sex Med; 2011 Dec; 8(12):3433-45. PubMed ID: 21995713 [TBL] [Abstract][Full Text] [Related]
16. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. Raina R; Pahlajani G; Agarwal A; Zippe CD BJU Int; 2007 Dec; 100(6):1317-21. PubMed ID: 17850385 [TBL] [Abstract][Full Text] [Related]
17. Erectile dysfunction--vasomotor actions of PGE1, its metabolites and other prostaglandins. Schrör K Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():533-8. PubMed ID: 7732902 [No Abstract] [Full Text] [Related]
18. [A trial of the use pf prostaglandin E1 (Edex, Caverject) for the diagnosis and treatment of erectile dysfunction]. Kovalev VA; Koroleva SV Urol Nefrol (Mosk); 1997; (2):41-4. PubMed ID: 9206883 [TBL] [Abstract][Full Text] [Related]